An Early Clinical Trial to Evaluate VGN-R09b for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency.

NCT05765981 | Recruiting Early Phase 1 DMC

• 1 other identifier: VGN-R09b-001
• Study Type: interventional
• Target: 6
• Locations: 1 country
• Sites: 1

Brief Summary

This early Phase trial is to prove the safety and efficacy of VGN-R09b to treat patients with AADC deficiency.

Conditions

Aromatic L-amino Acid Decarboxylase (AADC) Deficiency

Keywords

AADC, AAV9, CNS gene therapy

Outcome Measures

Primary Outcomes (2)

• Number of Adverse Events (AEs), Serious Adverse Events (SAEs)

  Number of Adverse Events (AEs), Serious Adverse Events (SAEs)

  Week 52

• Achievement Ratio of the four motor development milestones (Head control, Sit independently, Stand/stepping with support and Walk with minimal assistant)

  Achievement Ratio of the four motor development milestones (Head control, Sit independently, Stand/stepping with support and Walk with minimal assistant) according to PDMS-II score.

  Week 52

Study Arms (1)

Aromatic L-amino acid decarboxylase (AADC) deficiency

EXPERIMENTAL

This early Phase trial is to prove the safety and efficacy of VGN-R09b to treat patients with AADC deficiency.

Drug: VGN-R09b

Interventions

VGN-R09b DRUG

VGN-R09b will be injected into bilateral putamen by stereotactic surgery.（Through the SmartFlow Ventricular Cannula or the parenchymal injection tube actually used in the research center）

Aromatic L-amino acid decarboxylase (AADC) deficiency

Eligibility Criteria

• Age: 24 Months - 7 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• The child patient has to be ≥2 years old and \< 8 years old, or a head circumference big enough for surgery.
• Historical diagnosis of AADC deficiency with clinical symptoms consistency, AND confirmed by one of the lab tests: (1) CSF neurotransmitter profile demonstrating reduced HVA and 5-HIAA, and elevated L-Dopa concentrations; (2) Plasma AADC activity less than or equal to 5 pmol/min/mL, AND with Molecular genetic confirmation of homozygous or compound heterozygous mutation of IVS6+4A\>T in DDC.
• Motor development at baseline ≤3 months, and Failed to benefit from standard medical therapy (dopamine agonists, monoamine oxidase inhibitor or related form of Vitamin B6) at discretion of investigators.
• Stable medication regimen for treatment of AADC deficiency: (i.e. no new medications introduced for at least 6 months, and no existing medication dose changes for at least 3 months prior to Baseline).
• Parent(s)/legal guardian(s) with custody of subject must give their consent for subject to enroll in the study
• Parent(s)/legal guardian(s) of the subject must agree to comply with the requirements of the study, including providing disease information and support disease assessment of symptoms.

You may not qualify if:

• Intracranial neoplasm or any structural brain abnormality or lesion (e.g., severe brain atrophy, white matter degenerative changes), which, in the opinion of the study investigators, would confer excessive risk and/or inadequate potential for benefit.
• Presence of other significant medical or neurological conditions that would create an unacceptable operative or anesthetic risk (including congenital heart disease, respiratory disease with home oxygen requirement, history of serious anesthesia complications during previous elective procedures, history of cardiorespiratory arrest), liver or renal failure, malignancy, or HIV positive.
• Severe coagulopathy, or need for ongoing anticoagulant therapy.
• clinically active infection or with severe infection within 12 weeks before screening (e.g. adenovirus or herpes virus, pneumonia, sepsis, central nervous system infection).
• Previous stereotactic neurosurgery, or any gene/cell therapy.
• Received live vaccination within 4 weeks.
• Patients with anti-AAV9 neutralizing antibody titer over 1,200 folds.
• Contraindication to sedation during surgery or imaging studies (PET or MRI).

Sponsors & Collaborators

• Shanghai Jiao Tong University School of Medicine: lead
• Shanghai Vitalgen BioPharma Co., Ltd.: collaborator

Study Sites (1)

Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, No. 1678, Dongfang Road, Pudong New Area, Shanghai, 200127, China

RECRUITING

MeSH Terms

Conditions

Aromatic amino acid decarboxylase deficiency

Study Officials

• Jiwen Wang, Doctor

  Shanghai Children's Medical Center, affiliated to Shanghai Jiao Tong University School of Medicine

  STUDY CHAIR

Central Study Contacts

Jiwen Wang, Doctor

CONTACT

18916613192; wangjiwen@scmc.com.cn

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 18, 2023
• First Posted: March 13, 2023
• Study Start: January 30, 2023
• Primary Completion: February 20, 2025
• Study Completion (Estimated): February 20, 2029
• Last Updated: March 13, 2023

Record last verified: 2023-03

Locations

CN (1)